Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine
- PMID: 3479807
- PMCID: PMC299589
- DOI: 10.1073/pnas.84.23.8583
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine
Abstract
The major envelope glycoprotein of a human immunodeficiency virus (HIV) has been purified and was utilized as a prototype vaccine in chimpanzees. The 120,000-dalton glycoprotein (gp120) was purified from membranes of human T-lymphotropic virus (HTLV)-IIIB-infected cells and the final preparation contained low levels to no detectable HTLV-IIIB core antigen (p24) and low levels of endotoxin. Chimpanzees inoculated with gp120 responded by developing antibodies that precipitated radiolabeled gp120 and neutralized in vitro infection of HTLV-IIIB. Antibodies to HTLV-IIIB p24 were not detected in the gp120-immunized chimpanzees. Peripheral blood leukocytes from the vaccinated animals were examined for T4+ and T8+ cells, and no decrease in the T4/T8 ratio was found, indicating that immunization with a ligand (gp120) that binds to T4 has no detectable adverse effect on the population of T4+ cells. The only current animal model that can be reproducibly infected with HIV is the chimpanzee. Immunization of chimpanzees with HIV proteins will provide an experimental system for testing the effectiveness of prototype vaccines for preventing HIV infection in vivo.
Similar articles
-
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.J Virol. 1989 Dec;63(12):5046-53. doi: 10.1128/JVI.63.12.5046-5053.1989. J Virol. 1989. PMID: 2555541 Free PMC article.
-
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82. doi: 10.1073/pnas.85.12.4478. Proc Natl Acad Sci U S A. 1988. PMID: 2454471 Free PMC article.
-
Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.J Virol. 1987 Oct;61(10):3173-80. doi: 10.1128/JVI.61.10.3173-3180.1987. J Virol. 1987. PMID: 2442411 Free PMC article.
-
Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).Cancer Res. 1985 Sep;45(9 Suppl):4694s-4699s. Cancer Res. 1985. PMID: 2410115 Review.
-
NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection.Ann Intern Med. 1989 Mar 1;110(5):373-85. doi: 10.7326/0003-4819-110-5-373. Ann Intern Med. 1989. PMID: 2464961 Review.
Cited by
-
Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007310. doi: 10.1101/cshperspect.a007310. Cold Spring Harb Perspect Med. 2012. PMID: 22675663 Free PMC article.
-
Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.J Virol. 1988 Aug;62(8):2622-8. doi: 10.1128/JVI.62.8.2622-2628.1988. J Virol. 1988. PMID: 3392769 Free PMC article.
-
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees.J Virol. 1990 Aug;64(8):3674-8. doi: 10.1128/JVI.64.8.3674-3678.1990. J Virol. 1990. PMID: 2370678 Free PMC article.
-
Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.J Virol. 1992 Jul;66(7):4003-12. doi: 10.1128/JVI.66.7.4003-4012.1992. J Virol. 1992. PMID: 1602531 Free PMC article.
-
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.J Virol. 1998 Feb;72(2):1052-9. doi: 10.1128/JVI.72.2.1052-1059.1998. J Virol. 1998. PMID: 9444999 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical